Atai Life Sciences N.V. (NASDAQ: ATAI) is -28.20% lower on its value in year-to-date trading and has touched a low of $1.45 and a high of $6.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATAI stock was last observed hovering at around $1.89 in the last trading session, with the day’s gains setting it 0.02% off its average median price target of $11.00 for the next 12 months. It is also 90.9% off the consensus price target high of $21.00 offered by 14 analysts, but current levels are 62.55% higher than the price target low of $5.10 for the same period.
Currently trading at $1.91, the stock is -13.08% and -29.93% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.55 million and changing 1.06% at the moment leaves the stock -46.95% off its SMA200. ATAI registered -63.69% loss for a year compared to 6-month loss of -49.47%.
The stock witnessed a -39.56% gain in the last 1 month and extending the period to 3 months gives it a -33.22%, and is -1.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.85% over the week and 9.95% over the month.
Atai Life Sciences N.V. (ATAI) has around 81 employees, a market worth around $325.20M and $0.40M in sales. Distance from 52-week low is 31.72% and -69.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.00%).
Atai Life Sciences N.V. (ATAI) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Atai Life Sciences N.V. (ATAI) is a “Buy”. 14 analysts offering their recommendations for the stock have an average rating of 1.90, where 1 rate it as a Hold and 0 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Atai Life Sciences N.V. is expected to release its quarterly report on 05/15/2023.The EPS is expected to shrink by -9.00% this year.
Atai Life Sciences N.V. (ATAI) Top Institutional Holders
The shares outstanding are 156.61M, and float is at 150.49M with Short Float at 3.90%.
Atai Life Sciences N.V. (ATAI) Insider Activity
The most recent transaction is an insider purchase by Apeiron Investment Group Ltd.,the company’s10% Owner. SEC filings show that Apeiron Investment Group Ltd. bought 21,900 shares of the company’s common stock on Apr 29 at a price of $4.47 per share for a total of $97801.0. Following the purchase, the insider now owns 1.8 million shares.
Atai Life Sciences N.V. disclosed in a document filed with the SEC on Apr 28 that Apeiron Investment Group Ltd. (10% Owner) bought a total of 34,700 shares of the company’s common stock. The trade occurred on Apr 28 and was made at $4.46 per share for $0.15 million. Following the transaction, the insider now directly holds 1.78 million shares of the ATAI stock.
Still, SEC filings show that on Apr 27, Apeiron Investment Group Ltd. (10% Owner) acquired 19,803 shares at an average price of $4.64 for $91939.0. The insider now directly holds 1,742,702 shares of Atai Life Sciences N.V. (ATAI).
Atai Life Sciences N.V. (ATAI): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 2.09% up over the past 12 months and Novan Inc. (NOVN) that is -56.27% lower over the same period. Biogen Inc. (BIIB) is 32.36% up on the 1-year trading charts.